High BCL2 IHC expression in DLBCL — common in GCB and ABC subsets. 'Dual-expressor' (BCL2...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BCL2-EXPRESSION-DLBCL-NOS |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BCL2-EXPRESSION-IHC |
|---|---|
| Variant | BCL2 high expression by IHC (without rearrangement; 'dual-expressor' if MYC IHC also high) |
| Disease | DIS-DLBCL-NOS |
| ESCAT tier | IIIB |
| Recommended combinations | R-CHOP / pola-R-CHP per usual algorithm, venetoclax + R-CHOP (trial; CAVALLI) |
| Evidence summary | High BCL2 IHC expression in DLBCL — common in GCB and ABC subsets. 'Dual-expressor' (BCL2+MYC IHC ≥40-50% / ≥70%) is adverse but distinct from HGBL-DH (rearrangement-defined). Venetoclax + R-CHOP investigational (CAVALLI Ph2). Not biomarker-selected for venetoclax in DLBCL. |
Notes
ESCAT IIIB. Distinct from HGBL-DH which requires FISH-confirmed rearrangement.
Used By
No reverse references found in the YAML corpus.